Objective: To determine the cross-sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics.
| METHODS

| Participants
The MCSA is a prospective population-based study originally designed to characterize the incidence and prevalence of MCI in Olmsted County, Minnesota. 15 In 2004, Olmsted County residents between the ages of 70 and 89 were identified for recruitment using an agestratified and sex-stratified random sampling design to ensure that men and women were equally represented in each 10-year age strata.
The study was expanded to include those aged 50 years and older in 2012. The present study included 508 cognitively unimpaired at baseline participants with T2D, aged 50 years and older, who had complete cognitive assessments. The study protocols were approved by the Mayo Clinic and Olmsted Medical Center Institutional Review Boards.
All participants provided written informed consent.
| Participant assessment
Mayo Clinic Study of Aging follow-up visits after the baseline visit were scheduled to occur approximately every 15 months. Each visit included a physician examination, an interview by a study coordinator, and neuropsychological testing by a psychometrist. 15 The physician examination included a medical history review, complete neurological examination, and administration of the Short Test of Mental Status. 16 The study coordinator interview included collecting demographic information, medical history, and questions about memory to both the participant and an informant using the Clinical Dementia Rating scale. 17 The neuropsychological battery included 9 tests covering 4 domains: (1) Block Design subtests). 23 We calculated sample-specific z scores for all cognitive tests and created domain scores by averaging the z scores within each domain. We created a global cognitive score using the z transformation of the average of the 4 domains.
| Cognitive status determination
For each participant, cognitive performance in each domain was compared with the age-adjusted scores of individuals previously obtained using Mayo's Older American Normative Studies. [24] [25] [26] This approach relies on prior normative work and extensive experience with the measurement of cognitive abilities in an independent sample of subjects from the same population. Participants with scores approximately 1 standard deviation or more below the age-specific mean in the general population were considered for a diagnosis of possible MCI. At each visit, the final decision to diagnose MCI was based on a consensus agreement between the study coordinator, examining physician, and neuropsychologist who evaluated the participant, after taking into account education, prior occupation, visual or hearing deficits, and reviewing all other participant clinical information. 27 Individuals who performed in the normal cognitive range and did not meet
Key points
• Metformin use in type II diabetics was not associated with cognitive test performance.
• No other treatments were associated with cognitive test performance in type II diabetics.
• Metformin is associated with incident MCI.
criteria for MCI or dementia, which was diagnosed using DSM-IV criteria, 28 were deemed clinically unimpaired (CU). ; participants with a score of ≥13 were considered to have clinical depression. 33 Participants' blood samples collected in-clinic were used to determine APOE genotype.
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| Statistical analyses
We used Kruskal-Wallis equality-of-population rank test to examine participant characteristics by baseline treatment group. To make pairwise comparisons between treatment groups, we used Dunn's test for continuous variables and Fisher's exact test for dichotomous variables. We then developed propensity scores to account for differences in diabetes treatment use. Propensity scores were created using logistic models. Specifically, we estimated treatment effects from the available data by computing the average of the difference between the observed and potential effects for each subject in both groups. Propensity score estimations included age, sex, BMI, APOE ε4, CCI score, number of medications, duration of diabetes, diabetes complications, and HbA1C.
We used multivariate linear and logistic regression models to determine the cross-sectional association between diabetes treatment and cognitive test performance or MCI diagnosis. Models were adjusted for age, sex, education, BMI, APOE ε4, CCI score, number of medications, duration of diabetes, age of T2D diagnosis, diabetes complications, and the propensity score.
To determine the association between metformin use and change in cognitive test performance, we used mixed effects models only including participants who had 1 or more follow-up visits. Models were adjusted for age, sex, education, BMI, APOE ε4, CCI score, number of medications, duration of diabetes, and the propensity score.
Each model additionally included time (indicating change in cognitive test performance over follow-up) and an interaction term of treatment type and time (indicating change in cognitive test performance over follow-up as a function of baseline treatment type) as covariates.
We specified a random intercept and slope and used an unstructured covariance matrix. We additionally used competing risk regression models with age as the timescale and adjusted for sex, education, BMI, APOE ε4, CCI score, number of medications, duration of diabetes, diabetes complications, and the propensity score, to determine the association between treatment type and risk of MCI. Patients that progressed directly to dementia were excluded from analyses. Using graphical methods, we determined that proportional hazard assumptions were not violated. All statistical analyses were completed with Stata version 13.0 (StataCorp, College Station, TX).
| RESULTS
Participants with type II diabetes varied based on treatment by age, CCI score, number of medications, cognitive impairment status, duration of T2D, age of T2D diagnosis, T2D complications, death and loss to follow-up, and memory, visuospatial, and global z scores (Table 1) .
Pairwise comparisons between treatment groups are detailed in Table 1 . Cross-sectionally, there was no association between metformin use or any other diabetes treatment and global or domain-specific cognitive performance in multivariate models (Table 2 ).
In mixed effects models, we did not observe any cross-sectional association between diabetes treatment type and cognitive test performance, echoing findings from our linear regression models (Table 3) 
| Sensitivity analyses
We additionally investigated whether adjusting for chronic kidney disease altered the association between treatment type and cognitive outcomes, but found it did not. We further used interaction terms to investigate whether sex, CCI score, APOE ε4 genotype, diabetes duration (<8 vs. ≥8 years), or HbA1c (<6.4 or ≥6.4) were effect modifiers, but found no evidence that they were. Finally, we conducted analyses excluding those who switched from metformin use at baseline to another type of treatment during follow-up, but found this did not substantially alter the results.
Finally, we compared type II diabetics using combination therapy to the participants included in the study, who used only 1 type of treatment. At baseline, participants using combination therapy differed from the participants in the study on the following variables:
BMI, Charlson comorbidity index, number of medications, myocardial infarction, HbA1c, duration of diabetes, diabetes complications, and memory z score.
| DISCUSSION
In the present study of 508 older type II diabetics, we did not observe a cross-sectional or longitudinal association between metformin use and cognitive test performance. However, metformin, but not other oral medications or insulin, was associated with greater risk of MCI diagnosis over follow-up. We did not find any evidence of effect modification by sex, CCI score, APOE ε4 genotype, duration of diabetes, or HbA1c.
Metformin acts by activating 5′ adenosine monophosphate-activated protein kinase (AMPK), which in turn impacts vitamin B12
levels. Overactivation of AMPK is associated with increased
Alzheimer's-related pathology (phosphorylated tau, dendritic spine loss), but inhibiting AMPK protects against Alzheimer's pathology (amyloid-beta). 34 AMPK is regulated by tumor necrosis factor-α and adiponectin. Past findings suggest that there is an association between higher adiponectin and worse neurocognitive outcomes. 35 Therefore, future research needs to better understand the relationship between metformin use in T2D and neuroimaging and cognitive outcomes considering these mediating pathways. Findings will have clinical implications for treatment and management of T2D. Indeed, it has been suggested that clinicians regularly test B12 levels of patients with type II diabetes to manage this potential risk. 36 This is particularly pertinent as T2D is developed earlier in the lifecourse and management becomes increasingly chronic. Evidence from animal models suggests that metformin use is associated with cognition and dementia-related neuropathology, but the direction of the findings has been inconclusive. In a mouse model of neurodegeneration, treatment with metformin, as compared to treatment with donepezil, was associated with hippocampal neuron generation and better spatial memory performance. 10 Additionally, in adult male Wistar rats, metformin treatment was associated with better cognitive test performance and reduced inflammation and oxidative stress, which may have implications for reductions in tau phosphorylation. 11 Contrastingly, in a model of older mice those treated with metformin, as compared to controls, showed reduced neurotrophic factors and impaired visuospatial ability. 8 In a model of older mice, metformin treatment did not improve blood glucose or body weight and was associated with poorer visuospatial outcomes. 9 There is some suggestion that the differences observed in animal models may be because of age differences.
Past studies examining the association between metformin use and cognitive outcomes have shown mixed effects. In a sample of 211 diabetics aged 65 to 69 at baseline, the association of treatment (diet, oral hypoglycemic agents, insulin) with cognitive function was investigated over a period of 4 years. Participants who used only metformin (n = 23) showed significant protective effect on tests of verbal learning, working memory, and executive function. 13 Similarly, in a .002
Model adjusted for age, sex, education, BMI, APOE ε4, CCI, number of medications, T2D duration, age of T2D diagnosis, T2D complications, and propensity score.
longitudinal study of 204 metformin users, long-term metformin use differences in treatment groups that cannot be corrected with statistical methods. Additionally, we were not able to consider the mediating effects of vitamin B12 and proinflammatory markers. Vitamin B12 has not been measured in the MCSA, and proinflammatory levels are available in only a small subset of participants with type II diabetes. Examining the potential biological mechanisms linking metformin and neuroimaging and cognitive outcomes in large cohort studies will be critical to understanding the link between treatment and outcomes.
Finally, individuals who consent to participation in the MCSA tend to be healthier than individuals who are not, thus potentially introducing bias. However, because the MCSA uses a population-based sampling frame, this is less of a concern.
Finally, in this study, we examined only prevalent cases of T2D
and were not able to account for duration or dose of metformin.
Although we were able to adjust for duration of T2D, future research should further examine whether there is a difference between treatment and cognitive outcomes based on prevalent versus incident diabetes cases. Additionally, past evidence has suggested that decreases in serum B12 levels are dependent on dose of metformin. 37 Similarly, duration of metformin use may be associated to cognitive outcomes. 
